Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Buy” from Brokerages

Sutro Biopharma, Inc. (NASDAQ:STRO) has earned an average recommendation of “Buy” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $12.14.

STRO has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Sutro Biopharma in a report on Monday, November 18th. JMP Securities reaffirmed a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a research note on Monday, September 16th. Piper Sandler reiterated an “overweight” rating and issued a $11.00 target price on shares of Sutro Biopharma in a report on Friday, October 11th. Finally, Truist Financial cut their price target on Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 16th.

Hedge Funds Weigh In On Sutro Biopharma

Institutional investors have recently modified their holdings of the company. Gladius Capital Management LP acquired a new stake in Sutro Biopharma in the 3rd quarter valued at $28,000. ProShare Advisors LLC lifted its stake in shares of Sutro Biopharma by 49.1% in the second quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock valued at $48,000 after buying an additional 5,373 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Sutro Biopharma during the third quarter valued at about $77,000. Intech Investment Management LLC bought a new stake in shares of Sutro Biopharma during the third quarter worth about $91,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Sutro Biopharma in the 1st quarter worth about $92,000. 96.99% of the stock is owned by institutional investors and hedge funds.

Sutro Biopharma Stock Up 3.5 %

Shares of NASDAQ STRO opened at $2.69 on Thursday. The company has a market capitalization of $221.81 million, a PE ratio of -1.67 and a beta of 1.17. Sutro Biopharma has a twelve month low of $2.25 and a twelve month high of $6.13. The firm has a fifty day simple moving average of $3.51 and a 200 day simple moving average of $3.76.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.